Filgrastim (Filgrastim)


Indications and Reactions:

Role Indications Reactions
Secondary
Neutropenia 14.8%
Bone Marrow Conditioning Regimen 13.6%
Immunosuppression 9.9%
Diffuse Large B-cell Lymphoma 8.6%
Drug Use For Unknown Indication 8.6%
Haematopoietic Stem Cell Mobilisation 8.6%
Hepatitis C 4.9%
Acute Myeloid Leukaemia 3.7%
Antibiotic Therapy 3.7%
Granulocyte Count Decreased 3.7%
Myelodysplastic Syndrome 3.7%
Breast Cancer Metastatic 2.5%
Endocarditis Staphylococcal 2.5%
Haemoglobin Decreased 2.5%
Infection 2.5%
Thrombosis Prophylaxis 2.5%
Product Used For Unknown Indication 1.2%
Staphylococcal Infection 1.2%
Stem Cell Transplant 1.2%
Pyrexia 30.8%
Anxiety 7.7%
Thrombocytopenia 7.7%
White Blood Cell Count Decreased 7.7%
White Blood Cell Count Increased 7.7%
Medical Device Complication 3.8%
Palmar-plantar Erythrodysaesthesia Syndrome 3.8%
Renal Failure 3.8%
Respiratory Failure 3.8%
Septic Shock 3.8%
Sleep Disorder 3.8%
Subclavian Vein Thrombosis 3.8%
Subdural Haemorrhage 3.8%
Transplant Rejection 3.8%
Weight Increased 3.8%
Concomitant
Stem Cell Transplant 36.1%
Acute Myeloid Leukaemia 13.3%
Acute Lymphocytic Leukaemia 12.4%
Aplastic Anaemia 6.2%
B Precursor Type Acute Leukaemia 4.7%
Multiple Myeloma 4.1%
Bone Marrow Conditioning Regimen 3.3%
Myelodysplastic Syndrome 2.4%
Nuclear Magnetic Resonance Imaging 2.4%
Renal Transplant 2.4%
Hodgkin's Disease 1.8%
Immunosuppression 1.8%
Myeloid Leukaemia 1.8%
Bone Marrow Transplant 1.2%
Colorectal Cancer Metastatic 1.2%
Germ Cell Cancer 1.2%
Prophylaxis Against Transplant Rejection 1.2%
Acute Graft Versus Host Disease 0.9%
Colon Cancer 0.9%
Drug Use For Unknown Indication 0.9%
Stomatitis 21.1%
Vomiting 16.3%
Venoocclusive Liver Disease 8.2%
White Blood Cell Count Decreased 6.8%
Sepsis 6.1%
Unresponsive To Stimuli 4.1%
Pancytopenia 3.4%
Stem Cell Transplant 3.4%
Thrombocytopenia 3.4%
Wound Infection Staphylococcal 3.4%
Acute Graft Versus Host Disease 2.7%
Febrile Neutropenia 2.7%
Renal Failure Acute 2.7%
Septic Shock 2.7%
Thrombotic Microangiopathy 2.7%
Tumour Lysis Syndrome 2.7%
Plasmacytoma 2.0%
Ventricular Fibrillation 2.0%
Zygomycosis 2.0%
Cerebral Haemorrhage 1.4%

Drug Data